Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | São Paulo medical journal (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802013000400238 |
Resumo: | CONTEXT AND OBJECTIVES Sickle cell disease (SCD) is the most common genetic disorder among people of African descent, affecting approximately 3,500 newborns each year in Brazil. Hydroxyurea (HU) is the only effective drug to treating patients with SCD, thereby reducing morbidity and mortality. The objective was to analyze the effects of HU on SCD patients at our institution. DESIGN AND SETTING Retrospective study conducted at a sickle cell centre in Ribeirão Preto, São Paulo, Brazil. METHODS We analyzed clinical and laboratory data on 37 patients. The hematological parameters and clinical events that occurred during the year before and the first year of treatment with HU were analyzed. The mean dose of HU was 24.5 ± 5.5 mg/kg/day. RESULTS There were rises in three parameters: hemoglobin (8.3 g/dl to 9.0 g/dl, P = 0.0003), fetal hemoglobin (HbF) (2.6% to 19.8%, P < 0.0001) and mean cell volume MCV (89 to 105 fl, P = 0.001); and reductions in the numbers of leukocytes (10,050/µl to 5,700/µl, P < 0.0001), neutrophils (6,200/µl to 3,400/µl, P = 0.001), platelets (459,000/µl to 373,000/µl, P = 0.0002), painful crises (1.86 to 0.81, P = 0.0014), acute chest syndromes (0.35 to 0.08, P = 0.0045), infections (1.03 to 0.5, P = 0.047), hospitalizations (1.63 to 0.53, P = 0.0013) and transfusions (1.23 to 0.1, P = 0.0051). CONCLUSION The patients presented clinical and hematological improvements, with an increase in HbF and a reduction in the infection rate, which had not been addressed in most previous studies. |
id |
APM-1_feaeb698b594013db63931696e4fd47f |
---|---|
oai_identifier_str |
oai:scielo:S1516-31802013000400238 |
network_acronym_str |
APM-1 |
network_name_str |
São Paulo medical journal (Online) |
repository_id_str |
|
spelling |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in BrazilAnemia, sickle cellHydroxyureaFetal hemoglobinAcute chest syndromeErythrocyte indices CONTEXT AND OBJECTIVES Sickle cell disease (SCD) is the most common genetic disorder among people of African descent, affecting approximately 3,500 newborns each year in Brazil. Hydroxyurea (HU) is the only effective drug to treating patients with SCD, thereby reducing morbidity and mortality. The objective was to analyze the effects of HU on SCD patients at our institution. DESIGN AND SETTING Retrospective study conducted at a sickle cell centre in Ribeirão Preto, São Paulo, Brazil. METHODS We analyzed clinical and laboratory data on 37 patients. The hematological parameters and clinical events that occurred during the year before and the first year of treatment with HU were analyzed. The mean dose of HU was 24.5 ± 5.5 mg/kg/day. RESULTS There were rises in three parameters: hemoglobin (8.3 g/dl to 9.0 g/dl, P = 0.0003), fetal hemoglobin (HbF) (2.6% to 19.8%, P < 0.0001) and mean cell volume MCV (89 to 105 fl, P = 0.001); and reductions in the numbers of leukocytes (10,050/µl to 5,700/µl, P < 0.0001), neutrophils (6,200/µl to 3,400/µl, P = 0.001), platelets (459,000/µl to 373,000/µl, P = 0.0002), painful crises (1.86 to 0.81, P = 0.0014), acute chest syndromes (0.35 to 0.08, P = 0.0045), infections (1.03 to 0.5, P = 0.047), hospitalizations (1.63 to 0.53, P = 0.0013) and transfusions (1.23 to 0.1, P = 0.0051). CONCLUSION The patients presented clinical and hematological improvements, with an increase in HbF and a reduction in the infection rate, which had not been addressed in most previous studies. Associação Paulista de Medicina - APM2013-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802013000400238Sao Paulo Medical Journal v.131 n.4 2013reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/1516-3180.2013.1314467info:eu-repo/semantics/openAccessSilva-Pinto,Ana CristinaAngulo,Ivan LucenaBrunetta,Denise MenezesNeves,Fabia Idalina RodriguesBassi,Sarah CristinaSantis,Gil Cunha DeCovas,Dimas Tadeueng2013-11-19T00:00:00Zoai:scielo:S1516-31802013000400238Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2013-11-19T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse |
dc.title.none.fl_str_mv |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil |
title |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil |
spellingShingle |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil Silva-Pinto,Ana Cristina Anemia, sickle cell Hydroxyurea Fetal hemoglobin Acute chest syndrome Erythrocyte indices |
title_short |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil |
title_full |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil |
title_fullStr |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil |
title_full_unstemmed |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil |
title_sort |
Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil |
author |
Silva-Pinto,Ana Cristina |
author_facet |
Silva-Pinto,Ana Cristina Angulo,Ivan Lucena Brunetta,Denise Menezes Neves,Fabia Idalina Rodrigues Bassi,Sarah Cristina Santis,Gil Cunha De Covas,Dimas Tadeu |
author_role |
author |
author2 |
Angulo,Ivan Lucena Brunetta,Denise Menezes Neves,Fabia Idalina Rodrigues Bassi,Sarah Cristina Santis,Gil Cunha De Covas,Dimas Tadeu |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Silva-Pinto,Ana Cristina Angulo,Ivan Lucena Brunetta,Denise Menezes Neves,Fabia Idalina Rodrigues Bassi,Sarah Cristina Santis,Gil Cunha De Covas,Dimas Tadeu |
dc.subject.por.fl_str_mv |
Anemia, sickle cell Hydroxyurea Fetal hemoglobin Acute chest syndrome Erythrocyte indices |
topic |
Anemia, sickle cell Hydroxyurea Fetal hemoglobin Acute chest syndrome Erythrocyte indices |
description |
CONTEXT AND OBJECTIVES Sickle cell disease (SCD) is the most common genetic disorder among people of African descent, affecting approximately 3,500 newborns each year in Brazil. Hydroxyurea (HU) is the only effective drug to treating patients with SCD, thereby reducing morbidity and mortality. The objective was to analyze the effects of HU on SCD patients at our institution. DESIGN AND SETTING Retrospective study conducted at a sickle cell centre in Ribeirão Preto, São Paulo, Brazil. METHODS We analyzed clinical and laboratory data on 37 patients. The hematological parameters and clinical events that occurred during the year before and the first year of treatment with HU were analyzed. The mean dose of HU was 24.5 ± 5.5 mg/kg/day. RESULTS There were rises in three parameters: hemoglobin (8.3 g/dl to 9.0 g/dl, P = 0.0003), fetal hemoglobin (HbF) (2.6% to 19.8%, P < 0.0001) and mean cell volume MCV (89 to 105 fl, P = 0.001); and reductions in the numbers of leukocytes (10,050/µl to 5,700/µl, P < 0.0001), neutrophils (6,200/µl to 3,400/µl, P = 0.001), platelets (459,000/µl to 373,000/µl, P = 0.0002), painful crises (1.86 to 0.81, P = 0.0014), acute chest syndromes (0.35 to 0.08, P = 0.0045), infections (1.03 to 0.5, P = 0.047), hospitalizations (1.63 to 0.53, P = 0.0013) and transfusions (1.23 to 0.1, P = 0.0051). CONCLUSION The patients presented clinical and hematological improvements, with an increase in HbF and a reduction in the infection rate, which had not been addressed in most previous studies. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802013000400238 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802013000400238 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/1516-3180.2013.1314467 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
publisher.none.fl_str_mv |
Associação Paulista de Medicina - APM |
dc.source.none.fl_str_mv |
Sao Paulo Medical Journal v.131 n.4 2013 reponame:São Paulo medical journal (Online) instname:Associação Paulista de Medicina instacron:APM |
instname_str |
Associação Paulista de Medicina |
instacron_str |
APM |
institution |
APM |
reponame_str |
São Paulo medical journal (Online) |
collection |
São Paulo medical journal (Online) |
repository.name.fl_str_mv |
São Paulo medical journal (Online) - Associação Paulista de Medicina |
repository.mail.fl_str_mv |
revistas@apm.org.br |
_version_ |
1754209263529492480 |